Show simple item record

dc.contributor.authorLyu, Xuechan
dc.contributor.authorDu, Jiang
dc.contributor.authorZhan, Guilai
dc.contributor.authorWu, Yujie
dc.contributor.authorSu, Hang
dc.contributor.authorZhu, Youwei
dc.contributor.authorJarskog, Fredrik
dc.contributor.authorZhao, Min
dc.contributor.authorFan, Xiaoduo
dc.date2022-08-11T08:09:49.000
dc.date.accessioned2022-08-23T16:44:39Z
dc.date.available2022-08-23T16:44:39Z
dc.date.issued2018-03-05
dc.date.submitted2018-04-11
dc.identifier.citation<p>Front Pharmacol. 2018 Mar 5;9:181. doi: 10.3389/fphar.2018.00181. eCollection 2018. <a href="https://doi.org/10.3389/fphar.2018.00181">Link to article on publisher's site</a></p>
dc.identifier.issn1663-9812 (Linking)
dc.identifier.doi10.3389/fphar.2018.00181
dc.identifier.pmid29563871
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40544
dc.description.abstractObjective: The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia. Methods: Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon monoxide (CO) level and cigarettes smoked per week were measured at baseline and week 24. Results: There was no significant difference between two groups in changes in weight, BMI, fasting lipids, or cigarette smoking measures (p's > 0.05) Conclusion: Naltrexone and bupropion combination treatment didn't show weight loss or smoking cessation effect in patients with schizophrenia in this pilot study.Implications for future studies were discussed. ClinicalTrials.gov identifier: NCT02736474.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29563871&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2018 Lyu, Du, Zhan, Wu, Su, Zhu, Jarskog, Zhao and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectSchizophrenia
dc.subjectbupropion
dc.subjectnaltrexone
dc.subjectsmoking cessation
dc.subjectweight loss
dc.subjectMedical Pharmacology
dc.subjectMental Disorders
dc.subjectPharmacology
dc.subjectPsychiatry
dc.subjectSubstance Abuse and Addiction
dc.titleNaltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
dc.typeJournal Article
dc.source.journaltitleFrontiers in pharmacology
dc.source.volume9
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4361&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3350
dc.identifier.contextkey11943491
refterms.dateFOA2022-08-23T16:44:39Z
html.description.abstract<p>Objective: The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia.</p> <p>Methods: Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group). Body weight, body mass index (BMI), fasting lipids, smoking urge, expired carbon monoxide (CO) level and cigarettes smoked per week were measured at baseline and week 24.</p> <p>Results: There was no significant difference between two groups in changes in weight, BMI, fasting lipids, or cigarette smoking measures (p's > 0.05)</p> <p>Conclusion: Naltrexone and bupropion combination treatment didn't show weight loss or smoking cessation effect in patients with schizophrenia in this pilot study.Implications for future studies were discussed. ClinicalTrials.gov identifier: NCT02736474.</p>
dc.identifier.submissionpathoapubs/3350
dc.contributor.departmentPsychotic Disorders Program, Department of Psychiatry
dc.source.pages181


Files in this item

Thumbnail
Name:
fphar_09_00181.pdf
Size:
273.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2018 Lyu, Du, Zhan, Wu, Su, Zhu, Jarskog, Zhao and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as Copyright © 2018 Lyu, Du, Zhan, Wu, Su, Zhu, Jarskog, Zhao and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.